Women who are infected with HIV and are transitioning back to communities after serving jail time are less likely than their male counterparts to have a regular HIV care provider, to take and regularly adhere to an HIV medication regimen, and to have suppression of the virus.
NIDA plans to provide $750 travel awards to 27 junior investigators to present their research on women or sex/gender differences in any area of drug abuse at the annual meeting of the College on Problems of Drug Dependence in Phoenix, Arizona, June 13–18, 2015. Deadline to apply is December 5, 2014.
Women who reached their majority in states with policies that restricted teens’ access to tobacco products were less likely to smoke from ages 18-34 than women in states without those policies. The research did not demonstrate that the policies had a comparable impact on men’s smoking.
NIDA plans to provide $750 travel awards to 27 junior investigators to present their research on women or sex/gender differences in any area of drug abuse at the annual meeting of the College on Problems of Drug Dependence (CPDD) in San Juan, Puerto Rico, June 14‒19, 2014. Deadline to apply is December 2, 2013.
Men benefit more than women from nicotine replacement therapy for smoking cessation because nicotine affects a key neuroreceptor differently in the two sexes, a NIDA-sponsored study suggests. The findings highlight the need for alternative therapies for women smokers, and point to the female hormone progesterone as a potential therapeutic target.
Intensive case management was more effective in increasing treatment engagement and reducing alcohol consumption among depressed participants than among those who were not depressed, according to a followup analysis of a substance abuse treatment study involving women on welfare.
Sublingual buprenorphine is a safe and effective alternative to methadone for treating opioid dependence during pregnancy, finds the Maternal Opioid Treatment: Human Experimental Research (MOTHER) study, a NIDA-supported clinical trial. Women who received either medication had similar pregnancy and birth outcomes, but infants born to women who received buprenorphine had milder symptoms of neonatal opioid withdrawal.